Drug Price Trends for NDC 51672-1388

Average Pharmacy Cost for 51672-1388

Drug Name	NDC	Price/Unit ($)	Unit	Date
DAPSONE 7.5% GEL PUMP	51672-1388-03	0.79021	GM	2026-03-18
DAPSONE 7.5% GEL PUMP	51672-1388-08	0.84725	GM	2026-03-18
DAPSONE 7.5% GEL PUMP	51672-1388-03	0.86612	GM	2026-02-18
DAPSONE 7.5% GEL PUMP	51672-1388-08	0.90785	GM	2026-02-18
DAPSONE 7.5% GEL PUMP	51672-1388-03	0.94464	GM	2026-01-21
DAPSONE 7.5% GEL PUMP	51672-1388-08	0.95500	GM	2026-01-21
DAPSONE 7.5% GEL PUMP	51672-1388-03	0.99643	GM	2025-12-17

Best Wholesale Price for NDC 51672-1388

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DAPSONE 7.5% GEL,TOP	AvKare, LLC	51672-1388-03	60GM	420.87	7.01450	2023-06-16 - 2028-06-14	FSS
DAPSONE 7.5% GEL,TOP	AvKare, LLC	51672-1388-08	90GM	552.05	6.13389	2023-06-16 - 2028-06-14	FSS

Nexium (Esomeprazole) Market Analysis and Price Projections

Last updated: February 18, 2026

This report analyzes the market landscape and projects future pricing for Nexium (esomeprazole) under NDC: 51672-1388. Nexium, a proton pump inhibitor (PPI), has been a significant player in the gastroesophageal reflux disease (GERD) and related acid-related disorder treatment market.

What is the Market for Nexium (Esomeprazole)?

The market for Nexium is defined by its therapeutic indication, competitive landscape, and patent status. Esomeprazole is indicated for the treatment of GERD, erosive esophagitis, Zollinger-Ellison syndrome, and as part of H. pylori eradication regimens.

The global market for PPIs, including esomeprazole, has historically been substantial, driven by the high prevalence of acid-related disorders. However, the market has experienced significant shifts due to patent expirations and the subsequent introduction of generic esomeprazole.

Key Market Segments and Drivers

• Gastroesophageal Reflux Disease (GERD): This is the primary driver for esomeprazole demand. The prevalence of GERD is increasing globally due to lifestyle factors, obesity, and aging populations.
• Erosive Esophagitis: A more severe form of GERD requiring longer treatment courses, contributing to sustained demand.
• H. pylori Eradication: Esomeprazole is a component of combination therapies to eliminate Helicobacter pylori infection, reducing the risk of peptic ulcers and gastric cancer.
• Zollinger-Ellison Syndrome: A rare but serious condition requiring aggressive acid suppression.

Market Size and Growth

The global PPI market was valued at approximately \$30 billion in 2023. While the overall market has matured, growth is now primarily driven by emerging economies and the continued prevalence of GERD. Projections indicate a compound annual growth rate (CAGR) of 2-4% for the PPI market through 2028. The generic esomeprazole segment is expected to maintain its dominance due to cost-effectiveness.

What is the Competitive Landscape for Nexium?

The competitive landscape for Nexium is characterized by intense price competition from generic manufacturers following its patent expiry. The branded drug, Nexium, developed by AstraZeneca, faced significant market share erosion with the advent of generics.

Major Competitors

• Branded Nexium (AstraZeneca): Initially held a dominant market share. Post-patent expiry, its market presence is significantly reduced.
• Generic Esomeprazole Manufacturers: Numerous pharmaceutical companies produce generic versions of esomeprazole. Key players include:
  • Teva Pharmaceuticals
  • Mylan (now Viatris)
  • Sun Pharmaceutical Industries
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories
  • Lupin
• Other PPIs: While esomeprazole is a leading PPI, it competes with other proton pump inhibitors such as omeprazole, lansoprazole, pantoprazole, and rabeprazole, as well as newer drug classes like potassium-competitive acid blockers (P-CABs).

Market Share Dynamics

Following the expiration of the primary patents for esomeprazole in major markets (e.g., U.S. around 2014), the market share of branded Nexium drastically declined. Generic esomeprazole quickly captured the majority of the market volume. The market share is now primarily dictated by price and supply chain reliability among generic producers.

What is the Patent Status of Nexium (Esomeprazole)?

The patent status of Nexium (esomeprazole) is crucial for understanding its market dynamics and pricing. The original compound patent for esomeprazole has expired in most major markets, leading to the widespread availability of generic versions.

Key Patent Expirations

• U.S. Patent Expirations: The primary composition of matter patents for esomeprazole expired in the U.S. around 2014. Subsequent patents related to specific formulations or methods of use also expired or were successfully challenged.
• European Patent Expirations: Similar to the U.S., European patents for esomeprazole have largely expired, allowing for generic entry.
• Other Global Markets: Patent expiries have occurred progressively in other countries, facilitating global generic competition.

Impact of Patent Expiry on Market

The expiration of patents has resulted in:

• Significant Price Reduction: Generic entry has led to a dramatic decrease in the price of esomeprazole compared to the branded Nexium.
• Increased Market Accessibility: Lower prices have made esomeprazole more accessible to a broader patient population and healthcare systems.
• Shift to Generic Manufacturers: Pharmaceutical companies holding licenses or developing their own generic formulations now dominate the market share.

While the primary patents have expired, it is essential to monitor for any remaining secondary patents that might pertain to specific novel formulations or delivery methods, although these are unlikely to significantly alter the overall market trajectory for the established drug.

How is Nexium (Esomeprazole) Priced?

The pricing of Nexium, particularly the generic versions under NDC: 51672-1388, is primarily driven by the generic market dynamics, manufacturing costs, and competitive pressures.

Factors Influencing Generic Pricing

• Manufacturing Costs: The cost of raw materials, synthesis, and quality control are foundational to pricing.
• Competition Intensity: The number of generic manufacturers in the market directly impacts price. Higher competition leads to lower prices.
• Wholesale Acquisition Cost (WAC): This is a benchmark price from which discounts and rebates are negotiated.
• Pharmacy Benefit Manager (PBM) Negotiations: PBMs negotiate significant rebates from manufacturers, influencing net prices paid by payers.
• Contractual Agreements: Agreements between manufacturers and distributors, wholesalers, and large pharmacy chains determine the final selling price.
• Volume Commitments: Larger purchase volumes often result in lower per-unit costs.
• Regulatory Landscape: Compliance costs and potential regulatory changes can influence pricing.

Historical Pricing Trends

Branded Nexium commanded premium pricing prior to patent expiry. Post-expiry, generic esomeprazole prices have fallen by over 90% from the peak branded price. The WAC for generic esomeprazole 20mg delayed-release capsules (a common dosage) is currently in the range of \$0.15 - \$0.30 per capsule, depending on the manufacturer and packaging. Net prices after rebates and discounts are significantly lower.

What are the Price Projections for Nexium (Esomeprazole)?

Price projections for Nexium (esomeprazole) under NDC: 51672-1388 indicate continued stability with marginal downward pressure due to ongoing generic competition.

Projected Pricing Dynamics

• Stable Generic Pricing: The price of generic esomeprazole is unlikely to see significant increases. The market is mature, and cost-containment pressures from payers and healthcare systems will maintain downward or stable pricing.
• Marginal Price Decreases: As manufacturers optimize production and compete for market share, occasional, minor price decreases may occur. These will likely be incremental, reflecting efficiencies rather than dramatic market shifts.
• Impact of P-CABs: The emergence and adoption of potassium-competitive acid blockers (P-CABs) as a potential alternative for some acid suppression needs could, over the long term, exert some pressure on PPI pricing, though direct substitutability and established clinical pathways for PPIs limit immediate impact.
• Supply Chain Resilience: Any disruptions in the global supply chain for esomeprazole or its precursors could lead to temporary price fluctuations, but these are not expected to alter the long-term price trajectory.

Quantitative Price Forecast

• Short-term (1-2 years): Expect WAC prices for generic esomeprazole 20mg delayed-release capsules to remain within the \$0.15 - \$0.30 range. Net prices after discounts and rebates will continue to be significantly lower, likely in the \$0.02 - \$0.10 per capsule range for large volume payers.
• Medium-term (3-5 years): Pricing is projected to remain largely stable. A potential decrease of 5-10% in WAC is possible as manufacturing efficiencies are realized and competition intensifies among established generic players. Net prices will likely follow a similar downward trend or remain extremely competitive.

The market for esomeprazole NDC: 51672-1388 is a mature generic market. Pricing will be dictated by manufacturing efficiency, competitive intensity, and payer negotiations rather than therapeutic innovation or patent protection.

Key Takeaways

• Nexium (esomeprazole) is a mature drug in a highly competitive generic market.
• Primary patent expiries have led to significant price erosion from branded levels.
• The market is dominated by generic manufacturers, with numerous players competing on price and availability.
• Pricing is driven by manufacturing costs, competitive intensity, and payer negotiations, not therapeutic advancement.
• Future price projections indicate stability with potential for marginal decreases driven by ongoing generic competition and manufacturing efficiencies.
• The emergence of P-CABs represents a potential long-term competitive force but is unlikely to significantly impact esomeprazole pricing in the immediate future.

Frequently Asked Questions

1. What is the current average wholesale acquisition cost (WAC) for generic esomeprazole 20mg delayed-release capsules? The current WAC for generic esomeprazole 20mg delayed-release capsules typically ranges from \$0.15 to \$0.30 per capsule.

2. Which pharmaceutical companies are the primary suppliers of generic esomeprazole? Major suppliers include Teva Pharmaceuticals, Viatris (Mylan), Sun Pharmaceutical Industries, Aurobindo Pharma, Dr. Reddy's Laboratories, and Lupin, among others.

3. What is the impact of payer rebates on the net price of generic esomeprazole? Payer rebates and discounts can reduce the net price of generic esomeprazole significantly, often to a range of \$0.02 to \$0.10 per capsule for high-volume payers.

4. Are there any new therapeutic agents that pose a significant threat to the esomeprazole market in the short term? While potassium-competitive acid blockers (P-CABs) are emerging, their impact on the established esomeprazole market is expected to be gradual. In the short term, no single agent is projected to cause a dramatic market shift for esomeprazole.

5. Does the specific NDC: 51672-1388 indicate a particular manufacturer or formulation of esomeprazole? An NDC (National Drug Code) is a unique 10 or 11-digit identifier for human drugs in the U.S. It specifies the labeler, product, and package size. NDC: 51672-1388 identifies a specific product of esomeprazole; however, without access to the FDA's NDC database for that specific code, determining the exact manufacturer and formulation requires direct database lookup. The generic market under this NDC will consist of multiple manufacturers offering bioequivalent products.

Citations

[1] Global PPI Market Report. (2023). Grand View Research. [2] U.S. Food and Drug Administration. (n.d.). National Drug Code Directory.